Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Bouhlel L, et al. Bull Cancer. 2020 Sep;107(9):946-958. doi: 10.1016/j.bulcan.2020.04.019. Epub 2020 Jul 6. Bull Cancer. 2020. PMID: 32646604
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P. Ilie MI, et al. Among authors: bouhlel l. Ann Oncol. 2015 Jan;26(1):238-244. doi: 10.1093/annonc/mdu484. Epub 2014 Oct 24. Ann Oncol. 2015. PMID: 25344360 Free article.
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P. Ilie M, et al. Among authors: bouhlel l. Ann Oncol. 2016 Jan;27(1):147-53. doi: 10.1093/annonc/mdv489. Epub 2015 Oct 19. Ann Oncol. 2016. PMID: 26483045 Free article.
Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.
Sumodhee S, Guo L, Bouhlel L, Picard A, Otto J, Naghavi AO, Richier Q, Lévy A, Bondiau PY, Poudenx M, Passeron T, Lacour JP, Montaudié H, Doyen J. Sumodhee S, et al. Among authors: bouhlel l. Cancer Radiother. 2022 Nov;26(8):1045-1053. doi: 10.1016/j.canrad.2022.04.005. Epub 2022 Aug 1. Cancer Radiother. 2022. PMID: 35927166